Sale disclosed in SEC filing
Christopher J. Joyce, who serves as Chief Legal and Administrative Officer at Alignment Healthcare, Inc. (NASDAQ: ALHC), reported the sale of 18,013 shares of the company's common stock on April 1, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were sold at a weighted-average price of $17.7923, producing a total transaction value of $320,492. Reported sale prices ranged from $17.57 to $17.99.
Post-transaction holdings and market context
Following the disposition, Joyce directly holds 305,451 shares of Alignment Healthcare. The stock was trading near $17.85 at the time the filing was noted, with a year-to-date decline of 9.6% recorded for the share price.
Valuation and profitability outlook
Analysis from InvestingPro included with the company's updates indicates that ALHC appears undervalued relative to its Fair Value assessment. The same coverage reports that analysts expect Alignment Healthcare to return to profitability this year, after the company posted revenue growth of 46% prior to the most recent quarter.
Research access
For investors seeking expanded valuation and growth detail, a comprehensive Pro Research Report covering Alignment Healthcare is available on InvestingPro, which also provides reports for 1,400+ other U.S. equities.
Secondary offering by General Atlantic affiliate
In other corporate developments, an affiliate of General Atlantic, L.P. announced a secondary offering of 13.2 million shares of Alignment Healthcare, priced at $19.46 per share. The company has clarified that it will not receive any proceeds from that sale. The offering is expected to close in March 2026, with J.P. Morgan named as the underwriter for the transaction.
Recent financial performance
Alignment Healthcare reported robust fourth-quarter results. The company recorded a 25% year-over-year increase in membership and a 44.4% rise in revenue, results that exceeded expectations. Reported operating metrics included a medical benefit ratio of 87.7% and an improvement in the selling, general, and administrative (SG&A) expense ratio by about 115 basis points, bringing SG&A to 9.7%.
Brokerage coverage following results
Following the fourth-quarter 2025 disclosures, Raymond James reiterated a Strong Buy rating and left its price target at $27.00, citing the quarter's performance and outlook. Piper Sandler also reaffirmed its Overweight rating with a $30.00 price target after the same set of results.
Takeaway
The Form 4 filing documents a notable insider sale by a senior Alignment Healthcare executive while the company simultaneously posts strong operating results and navigates a sizeable secondary offering by an affiliated investor. Market participants can consult the available Pro Research Report for additional valuation analysis and company details.